Organism-specific therapeutic regimens for infectious tenosynovitis are provided below, including those for the following pathogens:
Methicillin-susceptible Staphylococcus aureus
Treatment regimens for methicillin-susceptible S aureus include the following[1, 2, 3, 4] :
Treatment courses should be individualized on the basis of initial staging, as well as clinical response to antibiotics, with or without irrigation, drainage, and debridement. Duration of therapy for uncomplicated infection is 7-14 days. For complicated infections, longer courses of 14-21 days are considered, depending on treatment response.
Methicillin-resistant Staphylococcus aureus
Treatment regimens for MRSA include the following[5, 1, 6, 7, 8, 9, 10] :
-
Doxycycline 100 mg PO q12h
or
-
Trimethoprim-sulfamethoxazole (160 mg/800 mg) 1 DS tablet PO BID
or
-
Clindamycin 300-600 mg PO/IV TID
or
-
Vancomycin 15-20 mg/kg q8-12h
or
-
Linezolid 600 mg PO/IV q12h
or
-
Daptomycin 4-6 mg/kg IV q24h
Note that vancomycin is the first-line drug of choice for empiric MRSA coverage for hospitalized patients.
Treatment courses should be individualized on the basis of initial staging, as well as clinical response to antibiotics, with or without irrigation, drainage, and debridement. Duration of therapy for uncomplicated infection is 7-14 days. For complicated infections, longer courses of 14-21 days are considered, depending on treatment response.
Streptococcus species
Treatment regimens for Streptococcus species include the following[11] :
-
Penicillin G 4 million units IV q4h
or
-
Clindamycin 300-600 mg PO/IV TID
or
-
Ceftriaxone 1 g IV q24h
or
-
Amoxicillin-clavulanate (875 mg/125 mg) PO BID
or
-
Ampicillin-sulbactam 1-2 g IV q6h
Treatment courses should be individualized on the basis of initial staging, as well as clinical response to antibiotics, with or without irrigation, drainage, and debridement. Duration of therapy for uncomplicated infection is 7-14 days. For complicated infections, longer courses of 14-21 days are considered, depending on treatment response.
Neisseria gonorrhoeae
Treatment regimens for N gonorrhoeae include the following[12] :
-
Ceftriaxone 1 g IM/IV q24h plus single-dose azithromycin 1 g PO
or
-
Cefotaxime 1 g IV q8h
plus single-dose azithromycin 1 g PO or
-
Ceftizoxime 1 g IV q8h plus single-dose azithromycin 1 g PO
With all regimens, treatment should be continued for 24-48 hours after symptom improvement, at which time therapy can be transitioned to cefixime 400 mg PO BID (or other oral agent, based on susceptibilities) to complete a total of at least 1 week of antimicrobial therapy.
Pasteurella multocida
Treatment regimens for P multocida include the following[13] :
-
Amoxicillin-clavulanate (875 mg/125 mg) PO BID
or
-
Ampicillin-sulbactam 1-2 g IV q6h
or
-
Doxycycline 100 mg PO BID
Treatment courses should be individualized on the basis of initial staging, as well as clinical response to antibiotics, with or without irrigation, drainage, and debridement. Duration of therapy for uncomplicated infection is 7-14 days. For complicated infections, longer courses of 14-21 days are considered, depending on treatment response.
Mycobacterium marinum
Treatment regimens for M marinum include the following[14, 15] :
-
Clarithromycin 500 mg PO BID
plus rifampin 600 mg PO daily
or
-
Clarithromycin 500 mg PO BID
plus ethambutol 15 mg/kg PO daily
or
-
Minocycline 100 mg PO BID
or
-
Doxycycline 100 mg PO BID
or
-
Trimethoprim-sulfamethoxazole (160 mg/800 mg) 1 DS tablet PO BID
Treatment is continued for 4-6 wk after symptoms resolve; duration of therapy is usually a minimum of 3 months.
For treatment of M tuberculosis infection, please refer to Tuberculosis Organism-Specific Therapy.
Sporothrix schenckii
Treatment regimens for S schenckii include the following[16, 17] :
-
Itraconazole 200 mg PO BID
or
-
Liposomal amphotericin B 3-5 mg/kg/day IV daily until resolution, then continue with itraconazole 200 mg PO BID
or
-
Deoxycholate amphotericin B 0.7-1 mg/kg/day until resolution, then continue with itraconazole 200 mg PO BID
Duration of therapy is at least 12 months.
Note that due to the significant adverse effect profile of amphotericin, regimens that contain this agent are used only in case of extensive disease and/or unresponsiveness to intraconazole.
Coccidioides species
Treatment regimens for Coccidioides species include the following[18, 19, 20, 21] :
-
Itraconazole 200 mg PO BID
or
-
Fluconazole 400-800 mg PO daily
or
-
Lipid amphotericin B 3-5 mg/kg IV daily until improving, then continue with itraconazole 200 mg PO BID
-
Duration of therapy: at least 6 to 12 months
Note: Consider higher doses of azoles based on clinical response. Reserve amphotericin for unresponsive disease due to its significant adverse effect profile.
Author
Jefferson R Roberts, MD Chief of Rheumatology Service, Tripler Army Medical Center; Assistant Clinical Professor of Medicine, Uniformed Services University of the Health Sciences
Jefferson R Roberts, MD is a member of the following medical societies: American College of Physicians, American College of Rheumatology, Society for Simulation in Healthcare
Disclosure: Nothing to disclose.
Coauthor(s)
Sharon W Chi, DO Resident Physician, Department of Internal Medicine, Tripler Army Medical Center
Sharon W Chi, DO is a member of the following medical societies: American College of Physicians
Disclosure: Nothing to disclose.
Victoria M F Mank, MD Resident Physician, Department of Internal Medicine, Tripler Army Medical Center
Victoria M F Mank, MD is a member of the following medical societies: American College of Physicians
Disclosure: Nothing to disclose.
Specialty Editor Board
Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference
Disclosure: Nothing to disclose.
Chief Editor
Thomas E Herchline, MD Professor of Medicine, Wright State University, Boonshoft School of Medicine; Medical Consultant, Public Health, Dayton and Montgomery County (Ohio) Tuberculosis Clinic
Thomas E Herchline, MD is a member of the following medical societies: Alpha Omega Alpha, Infectious Diseases Society of America, Infectious Diseases Society of Ohio
Disclosure: Received research grant from: Regeneron.
Additional Contributors
Jeremy W Docekal, MD Medical Intern, Department of Internal Medicine, Tripler Army Medical Center
Jeremy W Docekal, MD is a member of the following medical societies: Alpha Omega Alpha
Disclosure: Nothing to disclose.
Acknowledgements
Kelley Struble, DO Fellow, Department of Infectious Diseases, University of Oklahoma College of Medicine
Kelley Struble, DO is a member of the following medical societies: American College of Physicians and Infectious Diseases Society of America
Disclosure: Nothing to disclose.